Top Buy
Security | Buy | Sell | Buy (1M) | Sell (1M) | Price | Target price | Potential |
---|---|---|---|---|---|---|---|
Eli Lilly Corp. | 50 | 0 | 5 | 0 | €701.10 | €760.00 | 8.401% |
Biogen Inc. | 46 | 1 | 6 | 1 | €209.90 | €294.01 | 40.072% |
Vertex Pharmaceuticals Inc. | 45 | 2 | 6 | 0 | €399.30 | €408.36 | 2.268% |
Alnylam Pharmace. | 36 | 0 | 2 | 0 | €139.00 | €236.30 | 69.999% |
Regeneron Pharmaceuticals Inc. | 34 | 1 | 4 | 0 | €905.80 | €957.22 | 5.677% |
Johnson & Johnson | 32 | 1 | 3 | 0 | €140.46 | €196.74 | 40.065% |
Neurocrine Bioscience | 28 | 0 | 7 | 0 | €125.15 | €140.34 | 12.137% |
Pfizer Inc. | 31 | 4 | 3 | 0 | €26.40 | €40.66 | 54.013% |
Merck & Co. Inc. | 28 | 1 | 1 | 0 | €120.40 | €124.93 | 3.762% |
Cytokinetics Inc. | 26 | 1 | 3 | 0 | €53.50 | €84.57 | 58.078% |
Amgen Inc. | 25 | 0 | 5 | 0 | €288.50 | €297.31 | 3.054% |
Intra-Cellular Therapies Inc. | 24 | 0 | 7 | 0 | €61.00 | €79.55 | 30.417% |
Zoetis Inc. A | 23 | 1 | 5 | 0 | €156.62 | €200.06 | 27.734% |
AbbVie Inc. | 21 | 0 | 4 | 0 | €149.38 | €174.43 | 16.772% |
BioMarin Pharmaceutical Inc. | 20 | 0 | 3 | 0 | €74.46 | €102.62 | 37.818% |
TG Therapeutics Inc. | 22 | 4 | 5 | 0 | €16.06 | €28.06 | 74.770% |
Sutro Biopharma Inc | 18 | 0 | 0 | 0 | €3.84 | €11.05 | 187.719% |
Exelixis Inc. | 18 | 0 | 3 | 0 | €19.98 | €26.01 | 30.162% |
Pacira Pharmaceuticals | 18 | 0 | 3 | 0 | €27.40 | €47.53 | 73.460% |
United Therapeutics | 18 | 0 | 3 | 0 | €245.40 | €288.66 | 17.629% |
EyePoint Pharmaceuticals Inc. | 18 | 1 | 4 | 0 | €11.33 | €27.80 | 145.402% |
Krystal Biotech | 17 | 0 | 3 | 0 | €145.65 | €179.60 | 23.306% |
Ultragenyx Pharmaceutical Inc. | 17 | 1 | 3 | 0 | €38.00 | €84.74 | 123.011% |
Iovance Biotherapeutics Inc. | 20 | 4 | 1 | 1 | €10.10 | €22.78 | 125.498% |
Abbott Laboratories | 16 | 0 | 2 | 0 | €97.40 | €116.81 | 19.926% |